Imunon EBITDA TCAC 5A

Que fait Imunon ? Imunon, Inc. generates revenue by advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The company operates from its headquarters in Lawrenceville, New Jersey, and relies on a team of 31 full-time employees to drive its clinical and preclinical research efforts. Its business model centers on two platform technologies: the TheraPlas platform for developing immunotherapies and other anti-cancer nucleic acid-based therapies, and the PLACCINE platform for creating nucleic acid vaccines for infectious diseases and cancer. These platforms utilize synthetic delivery systems that are independent of viral vectors or devices to deliver nucleic acids. The company monetizes its pipeline through its lead clinical program, IMNN-001, which is a DNA-based immunotherapy designed for the localized treatment of advanced ovarian cancer. IMNN-001 functions by instructing the body to produce cancer-fighting molecules, such as interleukin-12 and interferon gamma, directly at the tumor site. Additionally, Imunon is conducting preclinical studies on a nucleic acid vaccine candidate targeting the SARS-CoV-2 virus to validate the capabilities of its PLACCINE platform, thereby establishing the efficacy of its broader technological framework for potential future applications. Imunon est l'une des entreprises les plus populaires sur Eulerpool.